Michael Landowski

Dr. Michael Landowski

Ophthalmology, Visual, and Anatomical Sciences, Wayne State University, Detroit, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2010 in Human Mutation
Verified
Journal Article
Open access
PDF file
IBIlenia Boria
Ilenia Boria
EGEmanuela Garelli
Emanuela Garelli
HGHanna T. Gazda
Hanna T. Gazda
AAAnna Aspesi
Anna Aspesi
PQPaola Quarello
Paola Quarello
IDIrma Dianzani
Irma Dianzani
Diamond‐Blackfan Anemia (DBA) is characterized by a defect of erythroid progenitors and, clinically, by anemia and malformations. DBA exhibits an autosomal dominant pattern of inheritance with incomplete penetrance. Currently nine genes, all encoding ribosomal proteins (RP), have been found mutated in approximately 50% of patients. Experimental evidence supports the hypothesis that DBA is primarily the result of defective ribosome synthesis. By means of a large collaboration among six centers, we report here a mutation update that includes nine genes and 220 distinct mutations, 56 of which are new. The DBA Mutation Database now includes data from 355 patients. Of those where inheritance has been examined, 125 patients carry a de novo mutation and 72 an inherited mutation. Mutagenesis may be ascribed to slippage in 65.5% of indels, whereas CpG dinucleotides are involved in 23% of transitions. Using bioinformatic tools we show that gene conversion mechanism is not common in RP genes mutagenesis, notwithstanding the abundance of RP pseudogenes. Genotype–phenotype analysis reveals that malformations are more frequently associated with mutations in RPL5 and RPL11 than in the other genes. All currently reported DBA mutations together with their functional and clinical data are included in the DBA Mutation Database. Hum Mutat 31:1269–1279, 2010.

19 March 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
HGHanna T. Gazda
Hanna T. Gazda
MPMilena Preti
Milena Preti
MSMee Rie Sheen
Mee Rie Sheen
MOMarie-Francoise O'Donohue
Marie-Francoise O'Donohue
AVAdrianna Vlachos
Adrianna Vlachos
ABAlan H. Beggs
Alan H. Beggs
Diamond–Blackfan anemia (DBA) is an inherited form of pure red cell aplasia that usually presents in infancy or early childhood and is associated with congenital malformations in ∼30–50% of patients. DBA has been associated with mutations in nine ribosomal protein (RP) genes in about 53% of patients. We completed a large‐scale screen of 79 RP genes by sequencing 16 RP genes (RPL3, RPL7, RPL8, RPL10, RPL14, RPL17, RPL19, RPL23A, RPL26, RPL27, RPL35, RPL36A, RPL39, RPS4X, RPS4Y1, and RPS21) in 96 DBA probands. We identified a de novo two‐nucleotide deletion in RPL26 in one proband associated with multiple severe physical abnormalities. This mutation gives rise to a remarkable ribosome biogenesis defect that affects maturation of both the small and the large subunits. We also found a deletion in RPL19 and missense mutations in RPL3 and RPL23A, which may be variants of unknown significance. Together with RPL5, RPL11, and RPS7, RPL26 is the fourth RP regulating p53 activity that is linked to DBA. Hum Mutat 33:1037–1044, 2012.

30 June 2013 in Human Genetics
Verified
Journal Article
Closed access
PDF file
Michael LandowskiMichael Landowski
Michael Landowski
MOMarie-Francoise O'Donohue
Marie-Francoise O'Donohue
CBChristopher Buros
Christopher Buros
RGRoxanne Ghazvinian
Roxanne Ghazvinian
NMNathalie Montel-Lehry
Nathalie Montel-Lehry
HGHanna T. Gazda
Hanna T. Gazda

11 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Michael LandowskiMichael Landowski
Michael Landowski
UKUna Kelly
Una Kelly
MKMikael Klingeborn
Mikael Klingeborn
MGMarybeth Groelle
Marybeth Groelle
JDJin-Dong Ding
Jin-Dong Ding
CRCatherine Bowes Rickman
Catherine Bowes Rickman
Significance: The complement factor H (CFH) Y402H polymorphism (rs1061170) imparts the strongest risk for age-related macular degeneration (AMD), the leading cause of blindness in the elderly. Popular thinking holds that the CFH H402 variant increases complement activation in the eye, predisposing susceptibility to disease. However, clinical trials of complement inhibitors in AMD patients have failed. Here we provide an explanation, showing CFH variant-specific differences in the presentation of AMD-like pathologies. We show that aged mice expressing the human H402, but not Y402 variant, (i) develop AMD-like symptoms and (ii) display differences in their systemic and ocular lipoprotein levels, but not in their complement activation, after diet. These findings support targeting lipoproteins for the treatment of AMD.

1 January 2015 in The American Journal of Pathology
Verified
Journal Article
Open access
JDJin-Dong Ding
Jin-Dong Ding
UKUna Kelly
Una Kelly
Michael LandowskiMichael Landowski
Michael Landowski
CTChristopher B. Toomey
Christopher B. Toomey
MGMarybeth Groelle
Marybeth Groelle
CRCatherine Bowes Rickman
Catherine Bowes Rickman
Complement factor H (CFH) is an important regulatory protein in the alternative pathway of the complement system, and CFH polymorphisms increase the genetic risk of age-related macular degeneration dramatically. These same human CFH variants have also been associated with dense deposit disease. To mechanistically study the function of CFH in the pathogenesis of these diseases, we created transgenic mouse lines using human CFH bacterial artificial chromosomes expressing full-length human CFH variants and crossed these to Cfh knockout (Cfh(-/-)) mice. Human CFH protein inhibited cleavage of mouse complement component 3 and factor B in plasma and in retinal pigment epithelium/choroid/sclera, establishing that human CFH regulates activation of the mouse alternative pathway. One of the mouse lines, which express relatively higher levels of CFH, demonstrated functional and structural protection of the retina owing to the Cfh deletion. Impaired visual function, detected as a deficit in the scotopic electroretinographic response, was improved in this transgenic mouse line compared with Cfh(-/-) mice, and transgenics had a thicker outer nuclear layer and less sub-retinal pigment epithelium deposit accumulation. In addition, expression of human CFH also completely protected the mice from developing kidney abnormalities associated with loss of CFH. These humanized CFH mice present a valuable model for study of the molecular mechanisms of age-related macular degeneration and dense deposit disease and for testing therapeutic targets.

1 September 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
UKUna L. Kelly
Una L. Kelly
DGDaniel Grigsby
Daniel Grigsby
MCMartha A. Cady
Martha A. Cady
Michael LandowskiMichael Landowski
Michael Landowski
NSNikolai P. Skiba
Nikolai P. Skiba
CRCatherine Bowes Rickman
Catherine Bowes Rickman
Strong evidence suggests that dysregulated lipid metabolism involving dysfunction of the retinal pigmented epithelium (RPE) underlies the pathogenesis of age-related macular degeneration (AMD), the leading cause of irreversible blindness in the elderly. A hallmark of AMD is the over-production of lipid and protein-rich extracellular deposits that accumulate in the extracellular matrix [Bruch’s membrane (BrM)] adjacent to the RPE. We analyzed Apolipoprotein A-1 (ApoA-1) containing lipoproteins isolated from BrM of elderly human donor eyes and found a unique proteome, distinct from HDL isolated from donor plasma of the same individuals. The most striking difference is higher concentrations of ApoB and ApoE, which bind to glycosaminoglycans (GAGs). We hypothesize that this interaction promotes lipoprotein deposition onto BrM GAGs, initiating downstream effects that contribute to RPE dysfunction/death. We tested this hypothesis using two potential therapeutic strategies to alter the lipoprotein/protein profile of these extracellular deposits. First, we used short heparan sulfate oligosaccharides to remove lipoproteins already deposited in both the extracellular matrix of RPE cells and in aged donor BrM tissue. Second, an ApoA-1 mimetic, 5A peptide, was demonstrated to modulate the composition and concentration of apolipoproteins secreted from primary porcine RPE cells. Significantly, in a mouse model of AMD this 5A peptide altered the proteomic profile of circulating HDL and ameliorated some of the potentially harmful changes to the protein composition resulting from the high fat, high cholesterol diet in this model. Together, these results suggest that targeting HDL interactions with BrM represents a new strategy to slow AMD progression in humans.